CN Bio Secures $17 Million in Funding to Revolutionize Preclinical Drug Discovery with Organ-on-a-Chip Technology

We are thrilled to announce that CN Bio, a pioneering leader in organ-on-a-chip (OOC) technology, has successfully raised $17 million in its latest funding round. This significant investment underscores the growing demand for innovative solutions in preclinical drug discovery, where accuracy and efficiency have become paramount. With our cutting-edge PhysioMimix® suite of microphysiological systems, CN Bio provides researchers with the tools necessary to predict human responses to drug exposure, improving the overall success rate of new medicines entering the market. This funding will be strategically allocated towards enhancing our robust portfolio of technologies, including our 3D-validated cells, consumable plates, and Contract Research Services, which have shown great promise in recapitulating the intricate microarchitecture and microenvironment of human organs in vitro. By advancing our multi-organ models, such as the Intestine/Liver and Lung/Liver combinations, we aim to offer superior alternatives to traditional animal models, enabling researchers to generate physiologically relevant data crucial for safely advancing drug candidates through in vitro studies and into clinical trials. The ongoing support we receive from investors not only fuels our commitment to scientific progress but also accelerates our mission to make drug development more rapid, cost-effective, and ethical by reducing the reliance on animal studies. At CN Bio, we are excited about what lies ahead and invite you to follow us for regular updates on our advancements. Together, we are transforming the landscape of drug discovery, making a meaningful impact on global health. It starts here.